{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-010580","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.002882+00:00","generated_at":"2026-05-27T00:49:45.056928+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Traws Pharma CFO Mark Guerin resigns; Nora Brennan named Interim CFO","bullets":["Mark Guerin resigned as CFO effective Feb 5, 2025; receives $250K in 9 monthly installments plus $150K lump sum.","Guerin gets $75K RSUs vesting over 2 years, accelerated vesting of all outstanding awards, option exercise extended to Feb 2026.","Nora Brennan appointed Interim CFO effective Feb 5; compensation $42K/month through July 5, 2025.","Brennan previously CFO at Spectrum Pharmaceuticals and TELA Bio; led TELA Bio through IPO.","If extended after July 5, Brennan eligible for $425K salary, 115K RSUs, and target bonus up to 50% of salary."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-010580","json":"https://secwatch.observer/filing/0001104659-25-010580.json","markdown":"https://secwatch.observer/filing/0001104659-25-010580.md","text":"https://secwatch.observer/filing/0001104659-25-010580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925010580/0001104659-25-010580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925010580/tm255838d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:49:45.056928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"579c980e8c","claim":"Mark Guerin resigned as Chief Financial Officer at Traws Pharma, Inc..","evidence_excerpt":"On February 5, 2025 (the “Termination Date”), Mark Guerin resigned from his position as the Chief Financial Officer of Traws Pharma, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925010580/0001104659-25-010580-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c30dedd46e","claim":"Nora Brennan was appointed as Interim Chief Financial Officer at Traws Pharma, Inc..","evidence_excerpt":"On February 5, 2025, the Company’s Board of Directors appointed Nora Brennan as the Company’s Interim Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925010580/0001104659-25-010580-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}